ArticleTuberculosis and respiratory diseases2023
Summary of Korean Asthma Guideline.
Article in Tuberculosis and respiratory diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 13 citations in OpenAlex.
- Real-World Safety of Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Asthma or Chronic Obstructive Pulmonary Disease (COPD), and Clinical Outcomes in COPD: Post-marketing Surveillance in Korea.Tuberculosis and respiratory diseases · 2026Article
- Consensus of Korean Asthma Study Group on Definition of Clinical Remission in Severe Asthma: A Modified Delphi Study.Tuberculosis and respiratory diseases · 2026Article
- Cough Assessment in Chronic Respiratory Diseases (COASESS): Findings from a Prospective Multicenter Cross-Sectional Study.Tuberculosis and respiratory diseases · 2026Article
- Metabolomic Clusters and Their Association with Small Airway Disease in Asthma.Journal of asthma and allergy · 2026Article
- Impact of Microplastic Exposure on Airway Inflammation in an Acute Asthma Murine Model.Tuberculosis and respiratory diseases · 2026Article
- Global prevalence of eligibility for biologic therapy in ATS/ERS-defined severe asthma: A systematic review.The World Allergy Organization journal · 2025Article
- To Achieve Asthma Remission, or to Achieve Asthma Control, That Is the Question in Asthma Treatment.Tuberculosis and respiratory diseases · 2025Article
- Effects of mesenchymal stem cells derived from human exfoliated deciduous teeth (SHEDs) on airway inflammation in a murine model of acute asthma.Cytotechnology · 2025Article
- Enhancing Asthma Management: Key Insights from the 10th Asthma Quality Assessment Program.Tuberculosis and respiratory diseases · 2025Article
- A Retrospective Study Evaluating Asthma Control in Patients on Fluticasone Propionate/Salmeterol Proactive Regular Dosing with a History of Uncontrolled Asthma.Pulmonary therapy · 2025Article
- Inhaled Corticosteroids and the Risk of Nontuberculous Mycobacterial Infection in Chronic Airway Disease: A Nationwide Population-Based Study.Tuberculosis and respiratory diseases · 2024Article
- The Wiser Strategy of Using Beta-Agonists in Asthma: Mechanisms and Rationales.Allergy, asthma & immunology research · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 10 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a chronic inflammatory airway disease that is characterized by variable airflow obstruction. The Korean Asthma Study Group of the Korean Academy of Tuberculosis and Respiratory Diseases has recently updated the Korean Asthma Guideline. This review summarizes the updated Korean Asthma Guideline. Asthma prevalence is increasing worldwide, and in Korea. Variable airflow obstruction can be confirmed by bronchodilator response or other tests, and should be established prior to the controller medication. A low-dose inhaled corticosteroid-formoterol is used to alleviate symptoms in all treatment step, and it can be used as a controller as well as reliever in steps 3-5. This approach is preferred, because it reduces the risk of severe exacerbations, compared to the use of short-acting β2-agonist as reliever. In severe asthma, phenotype/endotype based on the underlying inflammation should be evaluated. For type 2 severe asthma, the biologics should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.